

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Craig, et al.

Express Mail Label No.: EV321156885US

SERIAL No.: (not yet assigned)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service as Express Mail Post Office to Addressee Service under 37 C.F.R. 1.10 addressed to:

FILED: February 19, 2004

FOR: HYDRAZIDE AND
ALKOXYAMIDE ANGIOGENESIS
INHIBITORS

Mail Stop Petitions
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on:

GROUP ART NO.: (not yet assigned)

Date of Deposit: February 19, 2004

EXAMINER: (not yet assigned)

Tanya Parent 2/19/04
Tanya Parent Date

CASE NO.: 6690USC1

Mail Stop Petitions
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form.

Applicants submit herewith the Form PTO-1449 listing the references cited in this Information Disclosure Statement. The listed references are available for the Examiner to review in the file of the U.S. Serial No. 09/833,917. If the Examiner needs further copies of any cited references, the Examiner is respectfully requested to contact the undersigned attorney.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered.

Respectfully submitted,
Craig, et al.

ABBOTT LABORATORIES
Customer Number 23492
Telephone: (847) 937-0042
Facsimile: (847) 938-2623

Gregory W. Steele
Gregory W. Steele
Registration No. 33,796
Attorney for Applicants

DATE: February 19, 2004

SHEET 1_ of 1_

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98 (b))	ATTY. DOCKET NO.	SERIAL NO.
	6690USC1	(not yet assigned)
	APPLICANT(S)	
	R. A. Craig, et al.	
	FILING DATE	GROUP
	February 19, 2004	(not yet assigned)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
	AI	5,977,408	11/2/1999	Levin, et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC- ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION
	B1	9831710	20.01.2000	DE			YES NO
	B2	266950	11.05.1988	EP			
	B3	99/57098	11.11.1999	WO			
	B4	99/42436	26.08.1999	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	C1	Castro-Pichel, et al., "Synthesis & antiviral & cystatic activities," Nucleos. & Nucleit. 9(7):985-1000 (1990)
	C2	Griffith, E.C., "Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin," Chemistry and Biology 4(6):461-471 (1997)
	C3	Sin, Ny; "The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2," Proc. National Academy of Science USA 94:6099-6103 (1997)

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)

DATE: February 19, 2004

SHEET 1 of 1

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98 (b))	ATTY. DOCKET NO. 6690USC1	SERIAL NO. (not yet assigned)
	APPLICANT(S) R. A. Craig, et al.	
	FILING DATE February 19, 2004	GROUP (not yet assigned)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
	A1	5,977,408	11/2/1999	Levin, et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC- ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION	
							YES	NO
	B1	9831710	20.01.2000	DE				
	B2	266950	11.05.1988	EP				
	B3	99/57098	11.11.1999	WO				
	B4	99/42436	26.08.1999	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	C1	Castro-Pichel, et al., "Synthesis & antiviral & cystatic activities," Nucleos. & Nucleit. 9(7):985-1000 (1990)
	C2	Griffith, E.C., "Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin," Chemistry and Biology 4(6):461-471 (1997)
	C3	Sin, Ny; "The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2," Proc. National Academy of Science USA 94:6099-6103 (1997)

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)